20-MAY-2025 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 67 5 0 0 0 0 0 02/08/2021 78 34
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   9 4 1 1 0 0      
            19 4 1 1 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 50 14 9 2 1 0 03/02/2021 274 100
        2 Early V-O   96 29 17 10 5 1      
            146 43 26 12 6 1      
 
  MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 1 Y 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) 102 1 1 1 1 1 1 05/16/2025 132 33
            1 1 1 1 1 1      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 1 Daunorubicin + Cytarabine 335 3 3 3 1 0 0 09/25/2024 264 89
        2 Venetoclax + Daunorubicin + Cytarabine   3 3 3 1 0 0      
        3 Venetoclax + Azacitidine   4 4 3 2 1 0      
        4 (Daunorubicin + Cytarabine) Liposome   4 4 3 2 1 0      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   3 3 2 2 1 0      
            17 17 14 8 3 0      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   469 469 350 146 40 10 06/18/2024 328 125
            469 469 350 146 40 10      
 
    2 Y 2 Re-screening   41 41 37 18 2 0 06/18/2024    
            41 41 37 18 2 0      
 
    3 Y 3 Re-screening   6 6 6 4 2 0 06/18/2024    
            6 6 6 4 2 0      
 
    4 Y 4 Re-screening   1 1 1 1 0 0 06/18/2024    
            1 1 1 1 0 0      
 
Yes EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   6 1 1 0 0 0 02/24/2023 87 22
            6 1 1 0 0 0      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 243 85
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 0 0 0 0 0 08/13/2020 147 49
            11 0 0 0 0 0      
 
    1 E Total Registrations   5 0 0 0 0 0 08/13/2020    
            5 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   53 14 8 3 1 1 02/19/2021 167 55
            53 14 8 3 1 1      
 
    1 E Total Registrations   44 11 7 3 1 1 02/19/2021    
            44 11 7 3 1 1      
 
    2 E Total Registrations   37 8 4 2 0 0 02/19/2021    
            37 8 4 2 0 0      
 
  MM1OAEA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   4 4 4 1 1 0 12/02/2024 273 84
            4 4 4 1 1 0      
 
  MM1YACTG01-AML, New/Young/Intermediate, Ven+Chemo 1 E Total Registrations   2 2 0 0 0 0 10/14/2024 228 74
            2 2 0 0 0 0      
 

20-MAY-2025 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 167 55